About Connect Biopharma Holdings Limited - Ordinary Shares (CNTB)
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company focused on developing innovative therapies for immune-mediated diseases. The company specializes in harnessing its proprietary platform to create a new generation of biologics aimed at addressing various conditions, including those related to dermatology and respiratory health. With a commitment to advancing medical science, Connect Biopharma seeks to provide effective treatment options that improve the quality of life for patients suffering from chronic and debilitating illnesses. Through its research and development efforts, the company is dedicated to delivering breakthrough therapies that can make a significant impact on global healthcare. Read More
Connect Biopharma (NASDAQ:CNTB) reported top-line results from its Seabreeze STAT Phase II study of rademikibart in patients experiencing acute exacerbations of chronic obstructive pulmonary disease, or COPD. The company said the study met its primary objective, showing reductions in treatment failu
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026 at 11:30 a.m. ET.
Connect Biopharma (NASDAQ:CNTB) Chief Executive Officer Barry Quart said the company’s rademikibart program continues to show a differentiated clinical and mechanistic profile as the company awaits mid-2026 data from its SEABREEZE study.
Speaking during a fireside chat with H.C. Wainwright analyst
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 at 9:30 a.m. ET.
– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis –
ORLANDO, FL / ACCESS Newswire / April 7, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming virtual investor conference, Biotech Resurgence: Platforms and Pipelines of Today's Innovators, taking place April 16, 2026, from 9:30 a.m. to 4:00 p.m. ET.
– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near‑maximal responses achieved in ~90% of patients –
